1019115-10-6 Usage
Derivative of cyclopentanecarboxylic acid
Cyclopentanecarboxylic acid modified The compound is derived from cyclopentanecarboxylic acid by attaching a benzoyl group and a bromine atom at the 2-position.
Benzoyl group attachment
4-Bromobenzoyl group A benzoyl group, specifically a 4-bromobenzoyl group, is attached to the cyclopentanecarboxylic acid structure, contributing to the compound's properties and reactivity.
Bromine atom attachment
2-Position A bromine atom is attached to the 2-position of the cyclopentanecarboxylic acid structure, which can influence the compound's reactivity and properties.
Use as an intermediate
Synthesis of pharmaceuticals and agrochemicals 2-(4-Bromobenzoyl)cyclopentanecarboxylic acid is commonly used as an intermediate compound in the production of pharmaceuticals and agrochemicals, aiding in the creation of various drugs and chemicals.
Potential biological activities
Possible drug development The compound possesses potential biological activities, making it a useful building block for the development of new drugs.
Anti-inflammatory properties
Reduction of inflammation 2-(4-Bromobenzoyl)cyclopentanecarboxylic acid has been studied for its potential anti-inflammatory properties, which could be beneficial in the treatment of inflammatory conditions.
Anti-cancer properties
Inhibition of cancer cell growth The compound has also been studied for its potential anti-cancer properties, suggesting that it may be useful in inhibiting the growth of cancer cells and contributing to cancer treatment options.
Value in medicinal chemistry research
Development of new therapeutic agents Due to its potential biological activities and therapeutic properties, 2-(4-Bromobenzoyl)cyclopentanecarboxylic acid is a valuable compound in medicinal chemistry research, potentially leading to the development of new drugs and treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 1019115-10-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,1,9,1,1 and 5 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1019115-10:
(9*1)+(8*0)+(7*1)+(6*9)+(5*1)+(4*1)+(3*5)+(2*1)+(1*0)=96
96 % 10 = 6
So 1019115-10-6 is a valid CAS Registry Number.
1019115-10-6Relevant articles and documents
Process development of a diacyl glycerolacyltransferase-1 inhibitor
Ravn, Matthew M.,Wagaw, Seble H.,Engstrom, Kenneth M.,Mei, Jianzhang,Kotecki, Brian,Souers, Andrew J.,Kym, Philip R.,Judd, Andrew S.,Zhao, Gang
, p. 417 - 424 (2010)
A synthesis of a selective diacyl glycerolacyltransferase-1 (DGAT-1) inhibitor, 1, is described. The synthesis illustrates a diketone Favorskii reaction on 9 in place of the more common ketoester variant for generation of the dicarboxycyclopentane core, t
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor
Zhao, Gang,Souers, Andrew J.,Voorbach, Martin,Falls, H. Doug,Droz, Brian,Brodjian, Sevan,Yau, Yi Lau,Iyengar, Rajesh R.,Gao, Ju,Judd, Andrew S.,Wagaw, Seble H.,Ravn, Matthew M.,Engstrom, Kenneth M.,Lynch, John K.,Mulhern, Mathew M.,Freeman, Jennifer,Dayton, Brian D.,Wang, Xiaojun,Grihalde, Nelson,Fry, Dennis,Beno, David W. A.,Marsh, Kennan C.,Su,Diaz, Gilbert J.,Collins, Christine A.,Sham, Hing,Reilly, Regina M.,Brune, Michael E.,Kym, Philip R.
, p. 380 - 383 (2008/09/17)
A highly potent and selective DGAT-1 inhibitor was identified and used in rodent models of obesity and postprandial chylomicron excursion to validate DGAT-1 inhibition as a novel approach for the treatment of metabolic diseases. Specifically, compound 4a conferred weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depleted serum triglycerides following a lipid challenge in a dose-dependent manner, thus, reproducing major phenotypical characteristics of DGAT-1-/- mice.
Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
-
Page 23, (2008/06/13)
This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases.
